ARTICLE | Clinical News
Cip-isotretinoin regulatory update
February 6, 2012 8:00 AM UTC
Cipher said Health Canada accepted for review an NDS for Cip-isotretinoin to treat acne. The company expects a decision from the agency in 1Q13. Cipher licensed Cip-isotretinoin from Galephar Pharmaceutical Research Inc. (Juncos, Puerto Rico). The product is an oral semi-liquid capsule formulation of isotretinoin that uses Galephar's Lidose delivery system. ...